Cargando…

Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment

BACKGROUND: Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic Liver Disease prevalent all over the world. It has become more and more common in Japan, China and most western developed countries. The global prevalence rate is 25.24%, and the trend is increasing year by year. Related studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chun-Yong, Yang, Le-Le, Zhao, Pan, Yan, Pei-Zheng, Li, Jia, Zhao, Dong-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714250/
https://www.ncbi.nlm.nih.gov/pubmed/36451177
http://dx.doi.org/10.1186/s41065-022-00256-7
_version_ 1784842181766283264
author Sun, Chun-Yong
Yang, Le-Le
Zhao, Pan
Yan, Pei-Zheng
Li, Jia
Zhao, Dong-Sheng
author_facet Sun, Chun-Yong
Yang, Le-Le
Zhao, Pan
Yan, Pei-Zheng
Li, Jia
Zhao, Dong-Sheng
author_sort Sun, Chun-Yong
collection PubMed
description BACKGROUND: Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic Liver Disease prevalent all over the world. It has become more and more common in Japan, China and most western developed countries. The global prevalence rate is 25.24%, and the trend is increasing year by year. Related studies have shown that Cynarine has certain liver protection, lipid lowering and immune intervention effects. So, this study to systematically predict and analyze the mechanism of Cynarine in the treatment of non-alcoholic fatty liver disease (NAFLD) based on the integration of network pharmacology, molecular docking, and cell experiment. METHODS: We performed Heatmap and Venn diagram analyses to identify genes and targets in Cynarine treat NAFLD. The network of Cynarine-therapeutic targets and the protein-protein interaction network (PPI) was constructed. We used gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to visualize associated functional pathways. The Sybyl tool was used to dock the Cynarine with key therapeutic targets molecularly. Finally, cell experiments were applied to validate the role of Cynarine in the treatment of NAFLD. RESULTS: The Cynarine could act on 48 targets of NAFLD, and the role of CASP3, TP53, MMP9, ELANE, NOTCH1 were more important. The PPI network showed that immune and inflammation-related targets played a pivotal role. The KEGG analysis found that the PI3K-Akt signaling pathway, cell cycle and MAPK signaling pathway may be the main pathways for Cynarine to prevent and treat NAFLD. Molecular docking studies confirmed that Cynarine has good binding activity with therapeutic targets. Cynarine reduced the fat deposition ability of NAFLD model cells, and effectively reduced the levels of ALT and AST released by liver cells due to excessive lipid accumulation. We also found that Cynarine inhibited the expression of AKT1 and MAPK1. CONCLUSIONS: This study revealed that Cynarine could significantly reduce the fat deposition ability of NAFLD model cells, which may be closely related to the effective regulation of AKT1 and MAPK1 expression by Cynarine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41065-022-00256-7.
format Online
Article
Text
id pubmed-9714250
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97142502022-12-02 Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment Sun, Chun-Yong Yang, Le-Le Zhao, Pan Yan, Pei-Zheng Li, Jia Zhao, Dong-Sheng Hereditas Research BACKGROUND: Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic Liver Disease prevalent all over the world. It has become more and more common in Japan, China and most western developed countries. The global prevalence rate is 25.24%, and the trend is increasing year by year. Related studies have shown that Cynarine has certain liver protection, lipid lowering and immune intervention effects. So, this study to systematically predict and analyze the mechanism of Cynarine in the treatment of non-alcoholic fatty liver disease (NAFLD) based on the integration of network pharmacology, molecular docking, and cell experiment. METHODS: We performed Heatmap and Venn diagram analyses to identify genes and targets in Cynarine treat NAFLD. The network of Cynarine-therapeutic targets and the protein-protein interaction network (PPI) was constructed. We used gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to visualize associated functional pathways. The Sybyl tool was used to dock the Cynarine with key therapeutic targets molecularly. Finally, cell experiments were applied to validate the role of Cynarine in the treatment of NAFLD. RESULTS: The Cynarine could act on 48 targets of NAFLD, and the role of CASP3, TP53, MMP9, ELANE, NOTCH1 were more important. The PPI network showed that immune and inflammation-related targets played a pivotal role. The KEGG analysis found that the PI3K-Akt signaling pathway, cell cycle and MAPK signaling pathway may be the main pathways for Cynarine to prevent and treat NAFLD. Molecular docking studies confirmed that Cynarine has good binding activity with therapeutic targets. Cynarine reduced the fat deposition ability of NAFLD model cells, and effectively reduced the levels of ALT and AST released by liver cells due to excessive lipid accumulation. We also found that Cynarine inhibited the expression of AKT1 and MAPK1. CONCLUSIONS: This study revealed that Cynarine could significantly reduce the fat deposition ability of NAFLD model cells, which may be closely related to the effective regulation of AKT1 and MAPK1 expression by Cynarine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41065-022-00256-7. BioMed Central 2022-12-01 /pmc/articles/PMC9714250/ /pubmed/36451177 http://dx.doi.org/10.1186/s41065-022-00256-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Chun-Yong
Yang, Le-Le
Zhao, Pan
Yan, Pei-Zheng
Li, Jia
Zhao, Dong-Sheng
Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title_full Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title_fullStr Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title_full_unstemmed Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title_short Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
title_sort mechanisms of cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714250/
https://www.ncbi.nlm.nih.gov/pubmed/36451177
http://dx.doi.org/10.1186/s41065-022-00256-7
work_keys_str_mv AT sunchunyong mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment
AT yanglele mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment
AT zhaopan mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment
AT yanpeizheng mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment
AT lijia mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment
AT zhaodongsheng mechanismsofcynarinefortreatmentofnonalcoholicfattyliverdiseasebasedontheintegrationofnetworkpharmacologymoleculardockingandcellexperiment